The CSF neurogranin levels were significantly higher in patients with early symptomatic Alzheimer’s disease, and this differentiated them from controls, with diagnostic utility (0.71; 95% CI: 0.64–0.77) that was similar to other established cerebrospinal biomarkers [262] (Table 3). Here, NRGN is linked to early-onset autosomal dominant Alzheimer disease.